The gene-editing therapy OTQ923 normalized brain blood flow in 3 sickle cell disease patients, suggesting it may lower stroke ...

The first healthy volunteer has been dosed in a Phase 1 study of Cellarity's novel globin-switching therapy CLY-124 for ...

As a result of being a caregiver for her cousin, columnist Sylvia Amuta says she's now more caring, compassionate, and kind ...

Higher pain scores upon discharge from the emergency department may predict hospitalization in adolescents with SCD, a study ...

The first healthy volunteer has been dosed in a Phase 1 study of Cellarity's novel globin-switching therapy CLY-124 for sickle cell disease.

Considering a change to your treatment regimen? Columnist Mary Shaniqua shares tips to help patients and providers make an informed decision.

To mark four years of sharing his experiences through writing, columnist Dunstan Nicol-Wilson reflects on the journey with gratitude.